Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 36 matches for

Funding also supports the start of phase I/IIa study for lead vaccine, ITOP1

A photo of two Infinitopes scientists working in their laboratory.

Infinitopes granted Phase I/IIa Clinical Trial Application approval to evaluate precision vaccine targeting early-stage oesophageal cancer

Oxford, UK – 9 April 2025 – Infinitopes Ltd today announces that the UK Medicines and Healthcare products RegulatoryAgency (MHRA) has granted Clinical Trial Application (CTA) approval for the first-in-humanPhase I/IIa clinical trial of ITOP1, the company’s lead ‘off-the-shelf’ cancer vaccine.

Care Fertility and U-Ploid Biotechnologies announce research collaboration to improve egg quality in women of advanced maternal age

Care Fertility, a leading fertility treatment provider, and U-Ploid Biotechnologies, a pioneering reproductive health biotech, today announces a research collaboration aimed at improving egg quality and improve fertility treatment.

Infinitopes strengthens Board with two biotech leaders to advance precision immunotherapies into the clinic

Infinitopes welcomes Jo Brewer, PhD (CSO at Adaptimmune), and Dan Menichella (former CEO and CBO of CureVac's US subsidiary) as incoming Non-Executive Directors, bringing deep expertise in immunotherpay and oncology innovation.

Entelo Bio ushering in new ways of doing science

Entelo Bio, a venture backed biotechnology company pioneering the emerging isoform frontier of medicine, releases Flow Agent, an adaptive agentic (autonomous, AI-driven) based workflow management framework for bioinformatics workflows.

OXcan President and Co-Founder features as guest speaker on TheHill Digital Innovation Podcast

Andreas Halner, president and co-founder of Oxford Cancer Analytics (OXcan), who chats to our director, Megan Morys-Carter, about the company's inception, what makes the technology so revolutionary and the ever increasing success OXcan have been met with recently.

New ‘Super Test’ for prostate cancer developed in the UK by EDX Medical

CAMBRIDGE, England--(BUSINESS WIRE)--Scientists in Cambridge have developed a new ‘super test’ for prostate cancer in an effort to revolutionise screening and diagnosis of the disease and accelerate personalised treatment for patients.

U-Ploid Biotechnologies announces the appointment of Professor Alison Campbell to its advisory board

U-Ploid, a venture-backed biotechnology company developing next-generation fertility therapeutics, is pleased to announce the appointment of Professor Alison Campbell to its Advisory Board. In this key role, Professor Campbell will provide strategic guidance on company research programmes, working closely with the U-Ploid team to drive innovation in fertility treatments.

Oxford Cancer Analytics raises USD$11M in series A funding to transform early lung cancer detection and enable curative treatments

Dr. Heinrich Roder, expert in lung cancer proteomics liquid biopsy, appointed as Senior Vice President of Research and Development at OXcan.

AI-powered cancer immunotherapy discovery could be a step closer

TechBio startup, Exogene, is leveraging artificial intelligence (AI) to develop innovative immunotherapies with the potential to eliminate untreatable solid tumours in cancer patients. Through a collaboration with German company Alithea Bio, Exogene hopes to speed up cancer immunotherapy discovery and make it more cost-effective.

Exogene could be a step closer to AI-powered immunotherapy discovery

Through UK-Germany Collaborative R&D funding, Exogene is collaborating with the German company Alithea Bio, aiming to accelerate cancer immunotherapy discovery and make it more cost-effective.

Infinitopes to showcase breakthroughs on cancer vaccine development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial

Infinitopes, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announces that it will be presenting three posters on its pioneering cancer vaccine discovery and development, including one that has been recognised as a ‘top 100’ poster presentation, at the Society for Immunotherapy of Cancer (SITC) 2024, held in Houston, US, from 6-10th November.

Eterna Biologics: Revolutionising RNA therapeutics

We are excited to welcome Eterna Biologics, a University of Oxford biotech spinout company with a mission to unleash the full potential of RNA medicines. The company aims to enhance global health by expanding the applicability of RNA-targeting medicine to develop treatment for a wide range of human conditions.

Evolvere Biosciences accepted into the prestigious Y Combinator program

The team of University of Oxford students is making strides that could transform our approach to antibiotics.

U-Ploid thrilled to join the BioEscalator Community

U-Ploid Biotechnologies joins the BioEscalator to develop groundbreaking therapeutics that improve egg quality and revolutionise IVF.

RE-AIM Therapeutics: Targeting disease causal cells to cure autoimmunity

We are delighted to welcome RE-AIM Therapeutics to the BioEscalator community, a start-up focused on developing antibody-based curative therapies for inflammatory disorders, such as psoriasis and inflammatory bowel disease.

The BioEscalator welcomes SiGenex to its growing community

SiGenex is advancing genomic medicine with its innovative, artificial intelligence-powered in-hospital sequencing platform. The company's technology is designed to transform how hospitals, clinics, and medical centres perform targeted next-generation sequencing (NGS) tests.

Granza Bio grabs $7M seed from Felicis and YC to advance delivery of cancer treatments

In April 2024, the BioEscalator welcomed Granza Bio, a biotech startup focusing on developing novel immunotherapy delivery methods. The company has already attracted investor interest and closed a successful $7.14 million seed funding round led by Felicis and Refactor, with participation from Y Combinator.

Integrated cancer biotech Infinitopes secures £12.8M seed financing to enhance its Precision Immunomics(TM) antigen discovery technologies to target five more cancers

Funding also supports the start of phase I/IIa study for lead vaccine, ITOP1

Granza Bio: Pioneering personalised and targeted cancer therapeutics

The BioEscalator is pleased to welcome Granza Bio, a biotech startup founded by two PhD graduates in oncology and immunology from the University of Oxford. Granza Bio is pioneering a new era in cancer therapeutics by developing personalised and targeted cancer treatments using the body's own immune system.

Infinitopes has a double victory at the 15th Annual OBN Awards 2023

The OBN Awards recognise companies that demonstrate outstanding leadership, innovative practices, and significant contributions towards addressing clinical needs at different stages of development.

Load More

Similar stories